- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01324258
Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors
A Phase I Trial of GSK1120212 and GSK1120212 in Combination With Gemcitabine in Japanese Subjects With Solid Tumors
연구 개요
상세 설명
GSK1120212 has demonstrated anti-proliferative activity against a broad range of tumors cell lines and xenograft models. To date, MEK inhibitors have demonstrated evidence of both pharmacodynamic and clinical activity in early trials.
This is the first clinical experience in Japan with GSK1120212, a novel MEK inhibitor. This study is designed to identify recommended doses and regimens in Japanese subjects for the future development of GSK1120212.
This study will be conducted in subject with solid tumors, and GSK1120212 single agent treatment to assess safety, tolerability, PK and efficacy (Part 1) and combination treatment with gemcitabine in subjects with non-small cell lung cancer, pancreatic cancer, biliary cancer, urothelial cancer or other tumor types for which gemcitabine has been approved in 4-week schedule to assess safety, tolerability, PK and efficacy(Part 2) will be conducted in the same protocol.
연구 유형
등록 (실제)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
-
Osaka, 일본, 589-8511
- GSK Investigational Site
-
Tokyo, 일본, 181-8611
- GSK Investigational Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Correspond Part 1 (Single agent) and Part 2 (Combination)
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form
- Age 20 years old or older at consent given
- Able to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels
- Negative for hepatitis B surface (HBs) antigen, hepatitis virus Bc (HBc) antibody, and HBs antibody. HBs antigen-negative subjects who test positive for both HBc antibody and HBs antibody or either of them may be eligible when their HBV DNA quantification result is negative
- Negative HCV antibody test
- Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception from the time of the first dose of GSK1120212 until 16 weeks after the last dose of GSK1120212
- A female subject is eligible to participate if she is of;Non-childbearing potential females or female subjects with child-bearing potential must agree to use contraception until four weeks after the last dose of GSK1120212 to sufficiently minimize the risk of pregnancy at that point
Part 1 -Dose escalation single agent part
- Histologically or cytologically confirmed diagnosis of solid tumor malignancy that is not responsive to standard therapies or for which there is no approved or curative therapy. Subjects with primary brain tumor are excluded
- Adequate organ system functions as defined below; Absolute neutrophil count≥1,200/uL Hemoglobin≥9g/dL Platelets≥75,000/uL PT/INR and APTT≤1.3xULN Albumin≥2.5g/dL Total bilirubin≤1.5xULN AST and ALT≤2.5xULN Creatinine≤ULN OR Calculated creatinine clearance≥50mL/min OR 24-hour urine creatinine clearance≥50mL/min Left ventricular Ejection fraction≥LLN by ECHO or MUGA
Part 2 -Combination part
- Tumor type criteria;Histologically or cytologically confirmed diagnosis of solid tumor malignancy. Eligible are the cancers for which gemcitabine has been approved in 4-week schedule;1,000mg/m2 weekly for 3weeks followed by 1 week rest at the 4th week, including non-small cell lung cancer, pancreatic cancer, biliary cancer, and urothelial cancer, to which gemcitabine monotherapy is considered to be appropriate
- Adequate organ system functions as defined below; Absolute neutrophil count≥1,500/uL Hemoglobin≥9g/dL Platelets≥100,000/uL PT/INR and APTT1≤1.3xULN Albumin≥2.5g/dL Total bilirubin≤1.5xULN AST and ALT≤2.5xULN Creatinine≤ULN OR Calculated creatinine clearance≥50mL/min OR 24-hour urine creatinine clearance≥50mL/min Left ventricular Ejection fraction≥LLN by ECHO or MUGA
Exclusion Criteria:
Correspond Part 1 (Single agent) and Part 2 (Combination)
- Any serious and/or unstable pre-existing medical, psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures
- Use of an investigational anti-cancer drug within 28 days or five half-lives, whichever is shorter preceding the first dose of GSK1120212. Or use of an other investigational drug within 28 days or five half-lives, whichever is longer preceding the first dose of GSK1120212
- Previous treatment with a MEK inhibitor
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or subinvestigator, contraindicates their participation
- History of interstitial lung disease or pneumonitis
- Current use of a prohibited medication
- Any major surgery, radiotherapy, or immunotherapy within 21 days before initiation of GSK1120212. Or chemotherapy regimens with delayed toxicity within 21 days before initiation of GSK1120212. Or chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity within the two weeks before initiation of GSK1120212
- History or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR)
- Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression
- QTc B≥480 msecs
- History of acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting within the past 24 weeks
- History or evidence of current≥Class II congestive heart failure as defined by New York Heart Association
- History or evidence of current clinically significant uncontrolled arrhythmias
- History of HIV infection
- Evidence of severe or uncontrolled systemic diseases
- Unresolved toxicity greater than CTCAE (Version 3.0) Grade 1 from previous anti-cancer therapy except alopecia
- Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to dimethyl sulfoxide (DMSO)
- Pregnant or lactating female
- Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol
- Concurrent condition that in the investigator's opinion would jeopardize compliance with the protocol
- Unwillingness or inability to follow the procedures outlined in the protocol
Part 1 -Dose escalation single agent part
- History of another malignancy
- Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of drugs
Part 2 -Combination part
- History of another malignancy
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: GSK1120212
Part 1-Dose escalation will be conducted to assess PK after single dosing and safety, tolerability, PK and efficacy of GSK1120212 in Japanese subjects with solid tumors using a continuous daily dosing schedule.
|
Part1 and Part2
Part2
|
실험적: GSK1120212+Gemcitabine
Part 2-Further evaluate the safety, tolerability, PK, and efficacy of GSK1120212 in combination with gemcitabine in subjects with non-small cell lung cancer, pancreatic cancer, biliary cancer, urothelial cancer or other tumor types for which 4-week schedule of gemcitabine has been approved using the recommended dose from Part 1 (single agent).
|
Part2
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
Number of participants with adverse events as a measure of safety and tolerability
기간: Until a subject has a Dose Limiting Toxicity, withdraws from the study or dies
|
Until a subject has a Dose Limiting Toxicity, withdraws from the study or dies
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
To assess pharmacokinetics (PK) parameter (AUC, Cmax, tmax etc.) values for GSK1120212
기간: Cycle0, Cycle1 Day1,8,15,22, Cycle2 Day1 in Part 1
|
Individual subject parameter values as well as a descriptive summary (mean, standard deviation, median, minimum, maximum, geometric mean, and the standard deviation, CV% and 95% confidence interval of log-transformed parameters) by dose cohort will be reported.
|
Cycle0, Cycle1 Day1,8,15,22, Cycle2 Day1 in Part 1
|
To assess pharmacokinetics (PK) parameter (AUC, Cmax, tmax, etc.) values for GSK1120212 and Gemcitabine
기간: Cycle1 Day15 in Part2
|
Individual subject parameter values as well as a descriptive summary (mean, standard deviation, median, minimum, maximum, geometric mean, and the standard deviation, CV% and 95% confidence interval of log-transformed parameters) by dose cohort will be reported.
|
Cycle1 Day15 in Part2
|
Number of participants with the indicated tumor response defined by RECIST v1.1
기간: Every eight weeks during the study
|
Every eight weeks during the study
|
|
Serum level of cyctokines
기간: Cycle1 Day15 in Part1 and Part2
|
Cycle1 Day15 in Part1 and Part2
|
|
Tissue level of expression of the indicated protein including pERK and Ki67 if possible
기간: Cycle1 Day15 in Part1 and Part2
|
Cycle1 Day15 in Part1 and Part2
|
|
Tissue level of gene mutation including BRAF and KRAS if possible
기간: Cycle1 Day15 in Part1 and Part2
|
Cycle1 Day15 in Part1 and Part2
|
공동 작업자 및 조사자
스폰서
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- 114784
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
고형 종양에 대한 임상 시험
-
AstraZeneca모병Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, 위암, 유방암 및 난소암스페인, 미국, 벨기에, 영국, 프랑스, 헝가리, 캐나다, 대한민국, 호주
GSK1120212에 대한 임상 시험
-
National Cancer Institute (NCI)모집하지 않고 적극적으로진행성 악성 고형 신생물 | 전이성 악성 고형 신생물 | 간의 전이성 악성 신생물 | 절제 불가능한 고형 신생물미국, 캐나다
-
Jonsson Comprehensive Cancer CenterNovartis; Stand Up To Cancer; Prostate Cancer Foundation모집하지 않고 적극적으로
-
National Cancer Institute (NCI)Children's Oncology Group모집하지 않고 적극적으로
-
National Cancer Institute (NCI)완전한국소적으로 진행된 상피양 혈관내피종 | 전이성 상피양 혈관내피종 | 절제 불가능한 상피양 혈관내피종미국
-
National Cancer Institute (NCI)완전한
-
National Cancer Institute (NCI)완전한
-
University of UtahNovartis Pharmaceuticals모병전이성 췌장암 | 절제 불가능한 췌장암 | 3기 췌장암 | IV기 췌장암 | IIA기 췌장암 | IIB기 췌장암 | 2기 췌장암미국
-
National Cancer Institute (NCI)종료됨
-
National Cancer Institute (NCI)GlaxoSmithKline완전한IV기 유방암 | 재발성 유방암 | 침윤성 유방암 | 에스트로겐 수용체 음성 | HER2/Neu 음성 | 프로게스테론 수용체 음성 | 삼중음성 유방암미국